LBF20303PG05

Revision as of 06:39, 8 November 2010 by Editor (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



Prostaglandin D3
LBF20303PG05.png
Structural Information
(9α,15S) -Dihydroxy-11-oxo-prosta- (cis-5,trans-13,cis-17) -trien-1-oic acid
  • Prostaglandin D3
  • (9α,15S) -Dihydroxy-11-oxo-prosta- (5Z,13E,17Z) -trien-1-oic acid
Formula C20H30O5
Exact Mass 350.20932407
Average Mass 350.4492
SMILES C(=CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC
Physicochemical Information
PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway. Kulkarni_PS et al.
PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits. Bundy_GL et al. Goh_Y et al. Kulkarni_PS et al. However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation. Herschman_HR Smith_WL et al.
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20303PG05 See above. Bundy_GL et al. 1983
n.a. LBF20303PG05 See above. Goh_Y et al. 1988
n.a. LBF20303PG05 See above. Herschman_HR 1996
n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1987
n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1985
n.a. LBF20303PG05 See above. Smith_WL et al. 1996